Because tumor cells rely upon constitutive activation of STAT5, ERK-1/2 (Extracellular signal-regulated kinase 2), and AKT signaling pathways, targeting down-stream JAK2 targets, such as Pim kinases may have significant benefits in preventing JAK2 inhibitor resistance (Table 7). The gene discussed is MAPK1; the disease is neoplasm.